Study Overview The study aimed to evaluate the effectiveness of combining rituximab and intravenous immunoglobulin (IVIG) therapy alongside plasma exchange in patients experiencing severe central nervous system (CNS) demyelinating attacks. CNS demyelinating conditions, such as multiple sclerosis and neuromyelitis optica, can lead to significant neurological impairment, necessitating prompt and effective treatment strategies. Through a retrospective…
Read more: Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study